Clostridioides Difficile Infection: Prospective Cohort Analyzing Clinical Evolution and Bacterial Clearance

What this Trial Is About

Clostridioides difficile infection (CDI) is caused by a bacterium that can colonize the digestive system, especially in patients with risk factors like cancer or weakened immune systems. This infection can range from mild diarrhea to severe complications such as colitis or septic shock. Treatments typically include oral antibiotics like fidaxomicin or vancomycin, but recurrent infections are common and affect patients' quality of life. This research aims to better understand the factors leading to recurrence and improve prevention and treatment strategies. This observational study follows patients diagnosed with CDI over time to analyze how the bacteria clear from the digestive system. Patients will provide additional stool and saliva samples to study digestive microbiota changes and immune responses during and after treatment. The study tracks bacterial elimination and immune markers to gain insight into patient progress and infection dynamics. Participants will be asked to provide stool and saliva samples at various times, complete stool collection forms, and undergo monitoring for bacterial clearance and immune response. Researchers will measure how long it takes for the bacteria to clear after diagnosis and treatment, the impact of antibiotics, and the role of the immune system. The study helps inform better management of CDI and its recurrent forms, with participation lasting up to two months from diagnosis.

Clostridioides Difficile Infection: Analyzing CLInic Evolution and Bacterial Clearance